Califf Nomination Suffers 'Pile On': What Can FDA Do To Break Logjam?
Sen. Alexander and others remain optimistic as several holds and a filibuster threat emerge.
You may also be interested in...
US agency is convening two-day workshop on federal efforts to support healthcare provider education about pain management and safe use of the drugs; two University of Washington researchers say agency needs to exercise stricter oversight of opioid marketing and promotion.
‘Dramatic action’ needed to curb opioid epidemic, commissioner-nominee says, including potentially a cross-center approach to evaluating drugs and devices for pain, and new nomenclature for formulations currently labeled as abuse deterrent.
Nothing seems conventional about this presidency, but history suggests a nomination may not arrive for another month or longer, and thereafter confirmation could be swift.